Clinical Research Study| Volume 131, ISSUE 8, P933-938.e1, August 2018

Effectiveness and Safety of Rivaroxaban Versus Warfarin in Frail Patients with Venous Thromboembolism



      Frailty predicts poorer outcomes in patients receiving anticoagulation. We assessed the effectiveness and safety of rivaroxaban vs warfarin in frail patients experiencing venous thromboembolism.


      Using US MarketScan claims data from January 2012-December 2016, we identified frail patients (using the Johns Hopkins Claims-Based Frailty Indicator score) who had ≥1 primary hospitalization/emergency department visit diagnosis codes for venous thromboembolism, received rivaroxaban or warfarin as their first outpatient oral anticoagulant within 30 days of the index event, and had ≥12 months of insurance prior to the index venous thromboembolism. Differences in baseline covariates between cohorts were adjusted using inverse probability of treatment weights based on propensity scores. The primary endpoint was the composite of recurrent venous thromboembolism or major bleeding. Patient claims were tracked for up to 12 months after the index venous thromboembolism or until endpoint occurrence oral anticoagulant discontinuation/switch, insurance disenrollment, or end of follow-up. Cox regression was used to calculate hazard ratios (HRs) with 95% confidence intervals (CIs).


      Of 58,089 incident venous thromboembolism patients identified, 6869 (1365 rivaroxaban and 5504 warfarin users) were classified as frail. Rivaroxaban reduced patients' hazard of the composite of recurrent venous thromboembolism or major bleeding (HR 0.75; 95% CI, 0.57-0.98) and recurrent venous thromboembolism alone (HR 0.65; 95% CI, 0.44-0.97) compared with warfarin. No significant difference in major bleeding was observed between cohorts (HR 0.88; 95% CI, 0.61-1.27).


      Frail patients experiencing a venous thromboembolism and given rivaroxaban experience less recurrent venous thromboembolism, with at least as good bleeding outcomes, as patients prescribed warfarin.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to The American Journal of Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Villacampa-Fernández P.
        • Navarro-Pardo E.
        • Tarín J.J.
        • Cano A.
        Frailty and multimorbidity: two related yet different concepts.
        Maturitas. 2017; 95: 31-35
        • Bandeen-Roche K.
        • Xue Q.L.
        • Ferrucci L.
        • et al.
        Phenotype of frailty: characterization in the women's health and aging studies.
        J Gerontol A Biol Sci Med Sci. 2006; 61: 262-266
        • Prins M.H.
        • Lensing A.W.
        • Bauersachs R.
        • et al.
        Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies.
        Thromb J. 2013; 11: 21
        • Segal J.B.
        • Chang H.-Y.
        • Du Y.
        • Walston J.D.
        • Carlson M.C.
        • Varadhan R.
        Development of a claims-based frailty indicator anchored to a well-established frailty phenotype.
        Med Care. 2017; 55: 716-722
        • Hansen L.
        The Truven Health MarketScan Databases for life sciences researchers.
        (Available at)
        • White R.H.
        • Garcia M.
        • Sadeghi B.
        • et al.
        Evaluation of the predictive value of ICD-9-CM codedadministrative data for venous thromboembolism in the United States.
        Thromb Res. 2010; 126: 61-67
        • Fang M.C.
        • Fan D.
        • Sung S.H.
        • et al.
        Validity of using inpatient and outpatient administrative codes to identify acute venous thromboembolism: The CVRN VTE Study.
        Med Care. 2017; 55: e137-e143
        • Fried L.P.
        • Tangen C.M.
        • Walston J.
        • et al.
        Cardiovascular Health Study Collaborative Research Group. Frailty in older adults: evidence for a phenotype.
        J Gerontol A Biol Sci Med Sci. 2001; 56: M146-M156
        • Cunningham A.
        • Stein C.M.
        • Shung C.P.
        • Daugherty J.R.
        • Smalley W.E.
        • Ray W.A.
        An automated database case definition for serious bleeding related to oral anticoagulant use.
        Pharmacoepidemiol Drug Saf. 2011; 20: 560-566
        • Austin P.C.
        An introduction to propensity score methods for reducing the effects of confounding in observational studies.
        Multivariate Behav Res. 2011; 46: 399-424
        • Benchimol E.I.
        • Smeeth L.
        • Guttmann A.
        • et al.
        The Reporting of studies Conducted using Observational Routinely-collected health Data (RECORD) Statement.
        PLoS Med. 2015; 12 (e1001885)
        • Geldhof V.
        • Vandenbriele C.
        • Verhamme P.
        • Vanassche T.
        Venous thromboembolism in the elderly: efficacy and safety of non-VKA oral anticoagulants.
        Thromb J. 2014; 12: 21
        • Gandhi S.K.
        • Salmon W.
        • Kong S.X.
        • Zhao S.Z.
        Administrative databases and outcomes assessment: an overview of issues and potential utility.
        J Manag Care Spec Pharm. 1999; 5: 215-222